

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**SCHEDULE 13D**

**Under the Securities Exchange Act of 1934  
(Amendment No. 1)\***

**Enzo Biochem Inc.**  
(Name of Issuer)

**Common Stock**  
(Title of Class of Securities)

**294100102**  
(CUSIP Number)

**James C. Roumell**  
**Roumell Asset Management, LLC**  
**2 Wisconsin Circle, Suite 640**  
**Chevy Chase, MD 20815**  
**(301) 656-8500**

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

**July 22, 2019**  
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ]

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page

The information required on the remainder of this cover page shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Instructions).

CUSIP No.: 294100102

1	<b>NAME OF REPORTING PERSON:</b> Roumell Asset Management, LLC  <b>I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)</b> 52-2145132
2	<b>CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP</b> <input type="checkbox"/> (a) <input type="checkbox"/> (b)
3	<b>SEC USE ONLY</b>
4	<b>SOURCE OF FUNDS:</b> 00
5	<b>CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)</b> <input type="checkbox"/>
6	<b>CITIZENSHIP OR PLACE OF ORGANIZATION</b> Maryland
<b>NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH</b>	7 <b>SOLE VOTING POWER</b> 0
	8 <b>SHARED VOTING POWER</b> 0
	9 <b>SOLE DISPOSITIVE POWER</b> 0
	10 <b>SHARED DISPOSITIVE POWER</b> 0
11	<b>AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON</b> 0
12	<b>CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES</b> <input type="checkbox"/>
13	<b>PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)</b> 0%
14	<b>TYPE OF REPORTING PERSON</b> IA

CUSIP No.: 294100102

1	<b>NAME OF REPORTING PERSON:</b> James C. Roumell ("Roumell") <b>I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)</b>	
2	<b>CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP</b> <input type="checkbox"/> (a) <input type="checkbox"/> (b)	
3	<b>SEC USE ONLY</b>	
4	<b>SOURCE OF FUNDS:</b> PF	
5	<b>CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)</b> <input type="checkbox"/>	
6	<b>CITIZENSHIP OR PLACE OF ORGANIZATION</b> United States	
<b>NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH</b>	7	<b>SOLE VOTING POWER</b> 0
	8	<b>SHARED VOTING POWER</b> 0
	9	<b>SOLE DISPOSITIVE POWER</b> 0
	10	<b>SHARED DISPOSITIVE POWER</b> 0
11	<b>AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON</b> 0	
12	<b>CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES</b> <input type="checkbox"/>	
13	<b>PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)</b> 0%	
14	<b>TYPE OF REPORTING PERSON</b> IN	

**ITEM 1. SECURITY AND ISSUER:**

This Schedule 13D/A relates to the common stock of Enzo Biochem Inc. (the "Issuer"). The principal executive office of the Issuer is 527 Madison Avenue, New York, New York 10022.

**ITEM 2. IDENTITY AND BACKGROUND:**

This joint statement on Schedule 13D is being filed by Roumell Asset Management, LLC and by James C. Roumell (the "Reporting Persons").

Roumell Asset Management is organized as a Maryland limited liability company. Its principal address, and address of its principal business, is 2 Wisconsin Circle, Suite 640, Chevy Chase, Maryland 20815. Roumell Asset Management is a registered investment adviser.

Mr. Roumell's business address is 2 Wisconsin Circle, Suite 640, Chevy Chase, Maryland 20815. Mr. Roumell's present principal occupation is acting as the President of Roumell Asset Management, a registered investment adviser, whose address is set forth above.

During the last five years, none of the Reporting Persons have been convicted in any criminal proceeding (excluding traffic violations and similar misdemeanors). During the last five years, none of the Reporting Persons have been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction which resulted in or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.

**ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION:**

Not applicable.

**ITEM 4. PURPOSE OF TRANSACTION:**

The Reporting Persons sold shares of the common stock of the Issuer as part of their ordinary course of business based on their belief that the Issuer's stock is no longer undervalued.

Except as set forth above, the Reporting Persons do not have at this time any specific plans which would result in (a) the acquisition by the Reporting Persons of additional securities of the Issuer or the disposition by the Reporting Persons of securities of the Issuer; (b) any extraordinary corporate transactions such as a merger, reorganization or liquidation involving the Issuer or any of its subsidiaries; (c) any sale or transfer of a material amount of the assets of the Issuer or of any of its subsidiaries; (d) any change in the present management or board of directors, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board of directors; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) any change in the Issuer's charter or bylaws which may impede the acquisition of control of the Issuer by any person; (h) the Issuer's common stock being delisted from a national securities exchange or ceasing to be authorized to be quoted in an inter-dealer quotation system or a registered national securities association; (i) causing a class of equity securities of the Issuer to become eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (j) any action similar to those enumerated above.

**ITEM 5. INTEREST IN SECURITIES OF THE ISSUER:**

(a) See Items 11 and 13 of the cover pages of this Schedule 13D, which Items are incorporated herein by reference, for the aggregate number of shares and percentage of common stock beneficially owned by each of the Reporting Persons.

(b) See Items 7, 8, 9 and 10 of the cover pages to this Schedule 13D, which Items are incorporated herein by reference, for the aggregate number of shares of common stock beneficially owned by each of the Reporting Persons as to which there is sole or shared power to vote or direct the vote and/or sole or shared power to dispose or to direct the disposition of such shares of common stock.

(c) During the 60-day period ended July 24, 2019, Roumell Asset Management conducted the following transactions in the Issuer's common stock on behalf of its client advisory accounts, unless otherwise noted below. The share amount for any sale appears in parenthesis below, and all transactions were conducted in the open market for cash. Prices do not reflect brokerage commissions paid.

Mr. Roumell sold shares of the Issuer's common stock during the 60-day period ended July 24, 2019, which are included as part of the July 24, 2019 sale.

Date	No. of Shares	Aggregate Price
6/12/2019	(210,000)	(920,010.00) *
6/13/2019	(47,000)	(194,544.70) *
6/14/2019	(112,000)	(468,648.00) *
6/17/2019	(82,400)	(352,467.36)
6/17/2019	(36,428)	(156,458.26) *
6/18/2019	(43,000)	(180,390.20) *
6/19/2019	(52,600)	(216,090.56) *
6/20/2019	(33,900)	(139,383.00) *
7/15/2019	(37,000)	(144,639.90) *
7/16/2019	(50,000)	(192,500.00) *
7/18/2019	(290,700)	(1,103,537.56) *
7/19/2019	(7,117)	(26,638.93) *
7/22/2019	(19,270)	(70,496.01)
7/22/2019	(30,000)	(109,884.00) *
7/23/2019	(61,789)	(225,854.75)
7/23/2019	(684,365)	(2,497,932.25) *
7/24/2019	(45,708)	(165,837.77)

\* Denotes transactions by the Fund

(d) Roumell Asset Management's advisory clients have the right to receive or direct the receipt of dividends from, or the proceeds from the sale of, the shares of the Issuer's common stock. Investors in the Fund have the right to receive or direct the receipt of dividends from the shares of the Issuer's common stock, but proceeds from the sale of such shares become assets of the Fund. Mr. Roumell has the right, through his personal account, to receive dividends from, or the proceeds from the sale of, the shares of the Issuer's common stock.

(e) Not applicable.

**ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER:**

Not applicable.

**ITEM 7. MATERIALS TO BE FILED AS EXHIBITS:**

Exhibit 7.01 Joint Filing Agreement by and among the Reporting Persons, dated July 24, 2019.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

July 24 2019

James C. Roumell

By: /s/ James C. Roumell

Name: James C. Roumell

Title:

Roumell Asset Management, LLC

By: /s/ James C. Roumell

Name: James C. Roumell

Title: President

Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

Exhibit 7.01

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing on behalf of each of them this Schedule 13D (including further amendments thereto) with respect to the common stock of Enzo Biochem Inc., and that this Joint Filing Agreement be included as an exhibit to such joint filing.

This Joint Filing Agreement may be executed in one or more counterparts, and each such counterpart shall be an original but all of which, taken together, shall constitute but one and the same instrument.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of this 26th day of March 2019.

By: /s/ James C. Roumell  
James C. Roumell

ROUMELL ASSET MANAGEMENT, LLC

By: /s/ James C. Roumell  
James C. Roumell, President